NEU 3.15% $21.27 neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-141

  1. 1,539 Posts.
    lightbulb Created with Sketch. 131
    I agree with that we shouldn't get carried away with $100+ valuations in the short or medium term. It is pretty clear that we're pretty far away from our intrinsic value based on our existing business, let alone the potential. If ACAD comes out with decent numbers and sticks to guidance, and we get another good P2 set of results it wouldn't be unrealistic to expect $30+ (since we've already hit $25 on a single result), and the premium to $50 per share is rather minimal, particularly when you convert from AUD to USD.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$21.27
Change
0.650(3.15%)
Mkt cap ! $2.718B
Open High Low Value Volume
$20.84 $21.56 $20.76 $7.760M 364.5K

Buyers (Bids)

No. Vol. Price($)
2 1378 $21.24
 

Sellers (Offers)

Price($) Vol. No.
$21.29 218 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.